Synthesize Bio
Synthesize Bio develops generative genomics models that predict how human tissues and cells respond to drugs, diseases, and experimental interventions. Its platform enables drug development teams, clinical development teams, and biopharma partners to simulate clinical trial outcomes, optimize trial design, identify biomarkers, and augment limited datasets with virtual human cohorts. The organization aims to accelerate and de-risk clinical development by providing actionable predictions and insights grounded in large-scale RNA-seq data.
Facts
- HQ
- Seattle, WA, US
- Sectors
- Biotechnology Research
- Founded
- 2023
- Type
- Corporation Seattle business license
- Employees
- 21
- Registered name
- Synthesize Bio Seattle business license
- Stage
- Seed
- Founders
- Robert Bradley, PhD, Jeff Leek, PhD
Is this your organization? Claim it
Members see Synthesize Bio's funding rounds, amounts and investors.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Jeff Leek Co-founder, Co-CEO
-
Alice M. Walsh Executive, COO